MX2010003056A - Polimorfos de valomaciclovir. - Google Patents

Polimorfos de valomaciclovir.

Info

Publication number
MX2010003056A
MX2010003056A MX2010003056A MX2010003056A MX2010003056A MX 2010003056 A MX2010003056 A MX 2010003056A MX 2010003056 A MX2010003056 A MX 2010003056A MX 2010003056 A MX2010003056 A MX 2010003056A MX 2010003056 A MX2010003056 A MX 2010003056A
Authority
MX
Mexico
Prior art keywords
valomaciclovir
polymorphs
valomaciclovir polymorphs
crystalline forms
processes
Prior art date
Application number
MX2010003056A
Other languages
English (en)
Inventor
Mike H O'neill
Gregory P Butke
Original Assignee
Epiphany Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epiphany Biosciences Inc filed Critical Epiphany Biosciences Inc
Publication of MX2010003056A publication Critical patent/MX2010003056A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invenci?n se refiere a formas cristalinas de valomaciclovir, procedimientos para preparar formas cristalinas de valomaciclovir, composiciones farmac?uticas de las mismas y m?todos de uso de las mismas.
MX2010003056A 2007-09-21 2008-09-18 Polimorfos de valomaciclovir. MX2010003056A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99471907P 2007-09-21 2007-09-21
PCT/US2008/010937 WO2009042081A1 (en) 2007-09-21 2008-09-18 Valomaciclovir polymorphs

Publications (1)

Publication Number Publication Date
MX2010003056A true MX2010003056A (es) 2010-04-07

Family

ID=40511742

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003056A MX2010003056A (es) 2007-09-21 2008-09-18 Polimorfos de valomaciclovir.

Country Status (11)

Country Link
US (3) US20100240681A1 (es)
EP (1) EP2195319A4 (es)
JP (1) JP2010540440A (es)
KR (1) KR20100061823A (es)
CN (1) CN101827846B (es)
AU (1) AU2008305666B2 (es)
CA (1) CA2700227A1 (es)
HK (1) HK1148007A1 (es)
MX (1) MX2010003056A (es)
NZ (1) NZ583607A (es)
WO (1) WO2009042081A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011114336A1 (en) * 2010-03-15 2011-09-22 Hetero Research Foundation Process for the isolation of ganciclovir intermediate
WO2014047562A2 (en) * 2012-09-21 2014-03-27 Epiphany Biosciences Method of treating and/or preventing shingles and method of treating and/or preventing zoster associated pain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5245716B1 (es) 1970-07-10 1977-11-17
CN85101404A (zh) 1985-05-16 1987-01-17 帝人株式会社 头孢菌素衍生物的生产过程
JPH04235188A (ja) 1990-06-19 1992-08-24 Takeda Chem Ind Ltd ペネム化合物の結晶、その製造方法および抗菌剤
DE4235133A1 (de) 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
JP3623531B2 (ja) 1993-06-07 2005-02-23 ビーエーエスエフ アクチェンゲゼルシャフト 結晶質ｌ−アスコルビン酸−２−燐酸エステルマグネシウム塩の製造法
BR9609872A (pt) 1995-07-17 1999-03-23 Warner Lambert Co Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino
US5869493A (en) * 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
ES2186127T3 (es) * 1997-02-10 2003-05-01 Medivir Ab Sintesis de derivados de nucleosidos aciclicos.
US6184376B1 (en) * 1997-02-10 2001-02-06 Mediver Ab Synthesis of acyclic nucleoside derivatives
JPH11139975A (ja) * 1997-08-26 1999-05-25 Sankyo Co Ltd Ａ型モノアミンオキシダーゼ阻害薬
US6407241B1 (en) * 1999-11-08 2002-06-18 Merck & Co., Inc. Process and intermediates for the preparation of imidazolidinone αv integrin antagonists
SE0102273D0 (sv) 2001-06-26 2001-06-26 Medivir Ab Improved synthesis of branched acyclic nucleosides
JP4561698B2 (ja) * 2002-02-19 2010-10-13 小野薬品工業株式会社 縮合ピリダジン誘導体化合物およびその化合物を有効成分として含有する薬剤
BR0307780A (pt) 2002-02-19 2004-12-28 Ono Pharmaceutical Co Compostos derivados de piridazina fundida e medicamentos contendo os compostos como o ingrediente ativo
JP2004149451A (ja) * 2002-10-30 2004-05-27 Fuji Photo Film Co Ltd ジアゾニウム塩および記録材料
US7563805B2 (en) 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative

Also Published As

Publication number Publication date
US20130203785A1 (en) 2013-08-08
AU2008305666B2 (en) 2014-08-28
KR20100061823A (ko) 2010-06-09
NZ583607A (en) 2012-06-29
CN101827846A (zh) 2010-09-08
AU2008305666A1 (en) 2009-04-02
EP2195319A4 (en) 2011-09-14
HK1148007A1 (en) 2011-08-26
EP2195319A1 (en) 2010-06-16
JP2010540440A (ja) 2010-12-24
US9492456B2 (en) 2016-11-15
US20150051229A1 (en) 2015-02-19
US20100240681A1 (en) 2010-09-23
CN101827846B (zh) 2012-08-15
CA2700227A1 (en) 2009-04-02
WO2009042081A1 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
MY148253A (en) Azaadamantane derivatives and methods of use
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
MX2010007587A (es) Compuestos que comprenden un grupo ciclobutoxi.
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
WO2009104021A3 (en) Novel polymorphs and processes for their preparation
MX2009013354A (es) Compuestos de triarilo y composiciones que los contienen.
MX2010005530A (es) Activadores de receptor de vitamina d nuevos y metodos de elaboracion de los mismos.
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
WO2012015999A3 (en) Process for the preparation of imatinib mesylate
IN2012DN02793A (es)
WO2010049449A3 (en) Novel salts of sunitinib
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
MX2009006750A (es) Derivados de azaadamantano espirociclicos y metodos de uso.
WO2008021346A3 (en) Pure paliperidone and processes for preparing thereof
WO2008137134A3 (en) Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
WO2008075205A3 (en) Improved process for the preparation of voriconazole
MX339619B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
MX2012006524A (es) Proceso para la sintesis de compuestos intermedios de utilidad para preparar compuestos sustituidos de indazol y azaindol.
WO2010079045A3 (en) Crystalline salt forms of flibanserine
ZA201006669B (en) Process for the preparation of synthesis gas,ii

Legal Events

Date Code Title Description
FA Abandonment or withdrawal